Keros Therapeutics (KROS) EBT Margin (2019 - 2025)
Historic EBT Margin for Keros Therapeutics (KROS) over the last 6 years, with Q3 2025 value amounting to 61.03%.
- Keros Therapeutics' EBT Margin rose 135874200.0% to 61.03% in Q3 2025 from the same period last year, while for Sep 2025 it was 28.84%, marking a year-over-year increase of 288740000.0%. This contributed to the annual value of 5269.1% for FY2024, which is 960501100.0% up from last year.
- As of Q3 2025, Keros Therapeutics' EBT Margin stood at 61.03%, which was up 135874200.0% from 181.19% recorded in Q2 2025.
- In the past 5 years, Keros Therapeutics' EBT Margin ranged from a high of 1583500.0% in Q1 2021 and a low of 541000.0% during Q3 2023
- In the last 5 years, Keros Therapeutics' EBT Margin had a median value of 1503.16% in 2024 and averaged 61896.19%.
- Its EBT Margin has fluctuated over the past 5 years, first tumbled by 2000000000bps in 2022, then skyrocketed by 2000000000bps in 2024.
- Quarter analysis of 5 years shows Keros Therapeutics' EBT Margin stood at 27.6% in 2021, then tumbled by -387bps to 134.37% in 2022, then tumbled by -24077bps to 32486.01% in 2023, then soared by 95bps to 1503.16% in 2024, then skyrocketed by 96bps to 61.03% in 2025.
- Its last three reported values are 61.03% in Q3 2025, 181.19% for Q2 2025, and 75.03% during Q1 2025.